{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-043201","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2023-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.284323+00:00","generated_at":"2026-06-17T04:45:19.049685+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"President and COO Preston Klassen resigns; CMO Chris Cabell assumes duties","bullets":["Preston Klassen resigns as President and COO effective April 11, 2023.","CMO Chris Cabell will take over Klassen's duties.","Separation agreement accelerates 59,594 stock options; shares subject to 18-month lockup.","Klassen receives no additional severance beyond option vesting and net cashless exercise.","No cause for departure stated; agreement includes standard release and non-disparagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-043201","json":"https://secwatch.observer/filing/0001104659-23-043201.json","markdown":"https://secwatch.observer/filing/0001104659-23-043201.md","text":"https://secwatch.observer/filing/0001104659-23-043201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923043201/0001104659-23-043201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923043201/tm2312086d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:45:19.049685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2ae10a749","claim":"Chris Cabell changed role as Chief Medical Officer and Executive Vice President at Zura Bio Ltd.","evidence_excerpt":"Chris Cabell, the Company’s Chief Medical Officer and Executive Vice President, will be taking on Dr. Klassen’s duties going forward.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923043201/0001104659-23-043201-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"taking on duties of President and Chief Operating Officer"},{"label":"Role","value":"Chief Medical Officer and Executive Vice President"}],"fact_type":"executive_change"},{"claim_id":"f884de4715","claim":"Preston Klassen resigned as President and Chief Operating Officer at Zura Bio Ltd.","evidence_excerpt":"On April 6, 2023, Preston Klassen notified Zura Bio Limited (the “Company”) that he intended to resign as the Company’s President and Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923043201/0001104659-23-043201-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}